Semaglutide and body imaging study for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This study uses MRI scans to look at how the diabetes medication semaglutide affects body composition in people with type 2 diabetes and obesity. It may help doctors understand how this treatment works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 75 years old.
- You have type 2 diabetes with an HbA1c (average blood sugar) between 7% and 10.5%.
- Your body mass index (BMI) is between 30 and 45.
- You are planning to start or have just started the injectable medication semaglutide for diabetes.
- You are willing to have MRI scans and can fit in the scanner (no metal implants, no severe claustrophobia, and calf size less than 17 inches around).
- You have not taken other weight loss medications in the last 90 days, and you have not lost more than 10 pounds in that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
This study looks at how semaglutide (Ozempic or Wegovy) changes heart muscle and body muscle. It may help people with type 2 diabetes or those taking the drug for weight loss understand if their heart is affected.
This study tests whether combining two medications—CS0159 and semaglutide—can safely treat fatty liver disease, type 2 diabetes, and obesity together. If it works, it may help reduce liver fat and improve blood sugar control while supporting weight loss.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.